Pluri Inc. (PLUR), a clinical-stage biotechnology company focused on developing novel cell therapy products, is currently trading at $3.35, marking a 1.33% decline in recent trading sessions. This analysis reviews key technical levels, prevailing market context, and potential price scenarios for the stock, with no investment recommendations included. Key levels to monitor in upcoming sessions include a near-term support floor at $3.18 and a near-term resistance ceiling at $3.52, both of which ha
PLUR Stock Analysis: Pluri Inc. drops 1.33% to $3.35, key support levels assessed
PLUR - Stock Analysis
4697 Comments
544 Likes
1
Asya
Legendary User
2 hours ago
Where are the real ones at?
π 97
Reply
2
Dametra
Active Reader
5 hours ago
As a cautious person, this still slipped by me.
π 102
Reply
3
Anavia
Senior Contributor
1 day ago
Who else is curious but unsure?
π 251
Reply
4
Luerene
Legendary User
1 day ago
I shouldβve spent more time researching.
π 284
Reply
5
Didra
Experienced Member
2 days ago
Thatβs some award-winning stuff. π
π 20
Reply
Disclaimer: Not investment advice. For informational purposes only. Past performance does not guarantee future results. Trading involves substantial risk of loss.